Developing Topics

TRAILBLAZER-ALZ 4 demonstrated superiority of donanemab versus aducanumab at the 6-month primary endpoint of the percentage of participants achieving amyloid plaque clearance (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alzheimer's & dementia 2023-12, Vol.19 Suppl 24, p.e082529
Hauptverfasser:	Pain, Andrew, Ferguson, Margaret B, Wang, Hong, Salloway, Stephen, Lee, Elly, Papka, Michelle, Hu, Haoyan B, Lu, Ming, Oru, Ena B, Collins, Emily C, Brooks, Dawn A, Sims, John R
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Alzheimer Disease - drug therapy Antibodies, Monoclonal, Humanized - therapeutic use Female Humans Male Plaque, Amyloid - drug therapy Positron-Emission Tomography
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	TRAILBLAZER-ALZ 4 demonstrated superiority of donanemab versus aducanumab at the 6-month primary endpoint of the percentage of participants achieving amyloid plaque clearance (
ISSN:	1552-5279 1552-5279
DOI:	10.1002/alz.082529